These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 23423631

  • 1. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity.
    Yuan A, Wu J, Song C, Tang X, Qiao Q, Zhao L, Gong G, Hu Y.
    J Pharm Sci; 2013 May; 102(5):1626-35. PubMed ID: 23423631
    [Abstract] [Full Text] [Related]

  • 2. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X, Chen Q, Li Y, Tang H, Liu W, Yang X.
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [Abstract] [Full Text] [Related]

  • 3. Liver cancer targeting of Doxorubicin with reduced distribution to the heart using hematoporphyrin-modified albumin nanoparticles in rats.
    Chang JE, Shim WS, Yang SG, Kwak EY, Chong S, Kim DD, Chung SJ, Shim CK.
    Pharm Res; 2012 Mar; 29(3):795-805. PubMed ID: 21971829
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
    Guo H, Lai Q, Wang W, Wu Y, Zhang C, Liu Y, Yuan Z.
    Int J Pharm; 2013 Jul 15; 451(1-2):1-11. PubMed ID: 23618965
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
    Thao le Q, Byeon HJ, Lee C, Lee S, Lee ES, Choi YW, Choi HG, Park ES, Lee KC, Youn YS.
    Pharm Res; 2016 Mar 15; 33(3):615-26. PubMed ID: 26526555
    [Abstract] [Full Text] [Related]

  • 8. Enhanced tumor delivery and antitumor response of doxorubicin-loaded albumin nanoparticles formulated based on a Schiff base.
    Li F, Zheng C, Xin J, Chen F, Ling H, Sun L, Webster TJ, Ming X, Liu J.
    Int J Nanomedicine; 2016 Mar 15; 11():3875-90. PubMed ID: 27574421
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O, Tang Y, Ke X, Chen Y, Hu D, Tu J, Zhao L, Bourkaib N.
    Int J Pharm; 2015 Jan 30; 478(2):553-68. PubMed ID: 25455765
    [Abstract] [Full Text] [Related]

  • 11. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
    Nasr M, Nafee N, Saad H, Kazem A.
    Eur J Pharm Biopharm; 2014 Sep 30; 88(1):216-25. PubMed ID: 24813390
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
    Guo H, Zhang D, Li T, Li C, Guo Y, Liu G, Hao L, Shen J, Qi L, Liu X, Luan J, Zhang Q.
    J Pharm Sci; 2014 Mar 30; 103(3):987-93. PubMed ID: 24549734
    [Abstract] [Full Text] [Related]

  • 13. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.
    Ammar el-SM, Said SA, Suddek GM, El-Damarawy SL.
    Can J Physiol Pharmacol; 2011 Apr 30; 89(4):269-76. PubMed ID: 21526973
    [Abstract] [Full Text] [Related]

  • 14. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
    Byeon HJ, Thao le Q, Lee S, Min SY, Lee ES, Shin BS, Choi HG, Youn YS.
    J Control Release; 2016 Mar 10; 225():301-13. PubMed ID: 26826308
    [Abstract] [Full Text] [Related]

  • 15. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
    Ren S, Li C, Dai Y, Li N, Wang X, Tian F, Zhou S, Qiu Z, Lu Y, Zhao D, Chen X, Chen D.
    J Pharm Pharmacol; 2014 Sep 10; 66(9):1231-9. PubMed ID: 24716458
    [Abstract] [Full Text] [Related]

  • 16. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW, Yu HY, Guo H, Lou J, Wang ZM, Liu P, Sapin-Minet A, Maincent P, Hong XC, Hu XM, Xiao YL.
    Mol Pharm; 2015 Mar 02; 12(3):675-83. PubMed ID: 25584860
    [Abstract] [Full Text] [Related]

  • 17. Effect of co-treatment with doxorubicin and verapamil loaded into chitosan nanoparticles on diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Abo Mansour HE, El-Batsh MM, Badawy NS, Mehanna ET, Mesbah NM, Abo-Elmatty DM.
    Hum Exp Toxicol; 2020 Nov 02; 39(11):1528-1544. PubMed ID: 32519553
    [Abstract] [Full Text] [Related]

  • 18. A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy.
    Lee IH, Yu MK, Kim IH, Lee JH, Park TG, Jon S.
    J Control Release; 2011 Oct 10; 155(1):88-95. PubMed ID: 20854858
    [Abstract] [Full Text] [Related]

  • 19. Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles.
    Wang X, Zhen X, Wang J, Zhang J, Wu W, Jiang X.
    Biomaterials; 2013 Jun 10; 34(19):4667-79. PubMed ID: 23537667
    [Abstract] [Full Text] [Related]

  • 20. Exercise mitigates cardiac doxorubicin accumulation and preserves function in the rat.
    Jensen BT, Lien CY, Hydock DS, Schneider CM, Hayward R.
    J Cardiovasc Pharmacol; 2013 Sep 10; 62(3):263-9. PubMed ID: 23644988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.